Shuto Takashi, Inomori Shigeo, Fujino Hideyo, Nagano Hisato
Department of Neurosurgery, Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan.
J Neurosurg. 2006 Oct;105(4):555-60. doi: 10.3171/jns.2006.105.4.555.
The authors evaluated the results of Gamma Knife surgery (GKS) for the treatment of metastatic brain tumors from renal cell carcinoma (RCC).
The authors conducted a retrospective review of the clinical characteristics and treatment outcomes in 69 patients with metastatic brain tumors from RCC who underwent GKS at the authors' institution. Fifty-one patients were men, and 18 were women. The mean patient age was 64.2 years (range 45-85 years). The 69 patients underwent a total of 104 GKS procedures for treatment of 314 tumors. Eighteen patients received repeated GKS. Follow-up magnetic resonance (MR) imaging was used at a mean of 7.1 months after GKS to evaluate the change in 132 tumors after treatment. The mean prescription dose at the tumor margin was 21.8 Gy. The tumor growth control rate was 82.6%. Tumor volume and the delivered peripheral dose were significantly correlated with tumor growth control on univariate and multivariate analyses. Sixty (45.5%) of the 132 tumors assessed with MR imaging were associated with apparent peritumoral edema at the time of GKS. After treatment, peritumoral edema disappeared in 27 tumors, decreased in 13, was unchanged in 16, and progressed in four. Newly developed peritumoral edema after GKS was rare. The delivered peripheral dose was significantly correlated with control of peritumoral edema. The overall median survival time after GKS was 9.5 months. In this study, 34 patients died of systemic disease and 10 died of progressive brain metastases. Multivariate analysis showed that the number of lesions at the first GKS, the Karnofsky Performance Scale score at the first GKS, the recursive partitioning analysis classification, and the interval from diagnosis of RCC to brain metastasis were significantly correlated with survival time.
Gamma Knife surgery is effective for metastatic brain tumors from RCC. The disappearance rate of tumors is relatively low, but growth control is high. The delivered dose to the tumor margin is significantly correlated with the control of peritumoral edema. Gamma Knife surgery should be used as the initial treatment modality, if possible, even in patients with multiple metastases. Repeated GKS is recommended for newly developed brain metastases because of the low sensitivity of RCC to conventional radiation therapy.
作者评估了伽玛刀手术(GKS)治疗肾细胞癌(RCC)脑转移瘤的效果。
作者对在其机构接受GKS治疗的69例RCC脑转移瘤患者的临床特征和治疗结果进行了回顾性分析。其中男性51例,女性18例。患者平均年龄64.2岁(范围45 - 85岁)。这69例患者共接受了104次GKS手术,治疗314个肿瘤。18例患者接受了重复GKS治疗。在GKS术后平均7.1个月时进行随访磁共振(MR)成像,以评估132个肿瘤治疗后的变化。肿瘤边缘的平均处方剂量为21.8 Gy。肿瘤生长控制率为82.6%。在单因素和多因素分析中,肿瘤体积和外周给予剂量与肿瘤生长控制显著相关。在GKS时,132个接受MR成像评估的肿瘤中有60个(45.5%)伴有明显的瘤周水肿。治疗后,27个肿瘤的瘤周水肿消失,13个减轻,16个无变化,4个进展。GKS术后新出现的瘤周水肿罕见。外周给予剂量与瘤周水肿的控制显著相关。GKS术后总体中位生存时间为9.5个月。在本研究中,34例患者死于全身性疾病,10例死于进行性脑转移。多因素分析显示,首次GKS时的病灶数量、首次GKS时的卡氏功能状态评分、递归分区分析分类以及从RCC诊断到脑转移的间隔时间与生存时间显著相关。
伽玛刀手术对RCC脑转移瘤有效。肿瘤消失率相对较低,但生长控制率较高。肿瘤边缘给予的剂量与瘤周水肿的控制显著相关。即使在有多发性转移的患者中,如果可能,伽玛刀手术应作为初始治疗方式。由于RCC对传统放射治疗敏感性低,对于新出现的脑转移瘤建议进行重复GKS治疗。